companydata.dkAbacus Medicine Pharmaceuticals ApS: Financial statements 2024
CVR: 39192063
Abacus Medicine Pharmaceuticals ApS (CVR 39192063) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -64,000 and a net result of DKK -2,436,000 compared with DKK 1,385,541 the year before. Equity amounted to DKK 19,747,000. The solvency ratio was 35.3%.
- Gross Profit
- -64,000 kr.
- Profit/Loss
- -2,436,000 kr.
- Equity
- 19,747,000 kr.
- Total Assets
- 55,940,000 kr.
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -64 t. | -2.4 mio. | 19.7 mio. | 0 |
| 2023 | - | -73 t. | 1.4 mio. | 22.2 mio. | 0 |
| 2022 | - | -36 t. | -4.6 mio. | 20.8 mio. | 0 |
| 2021 | - | -43 t. | 2.8 mio. | 25.4 mio. | 0 |
| 2020 | - | -63 t. | 188 t. | 22.6 mio. | 0 |
How creditworthy is Abacus Medicine Pharmaceuticals ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2024
Abacus Medicine Pharmaceuticals ApS has published its annual report for 2023. Gross profit came to DKK -72,855, and the net result was DKK 1,385,541.
About Abacus Medicine Pharmaceuticals ApS
Abacus Medicine Pharmaceuticals ApS is a Danish company of the type Anpartsselskab based in København V, founded in 2017. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Flemming Wagner. The company is owned by ABACUS MEDICINE A/S. In 2025, the company reported a gross profit of DKK -80,000 and a net result of DKK -5,483,000 compared with DKK -2,436,000 the year before. Equity amounted to DKK 14,264,000.